Inhibition of intestinal FXR via glycoursodeoxycholic acid (GUDCA) improved mice obesity, whereas deconjugation of GUDCA by Bacteroides fragilis in the gut led to glucose intolerance and abrogated the metabolic benefits of metformin treatment (Sun et al., 2018). The gene discussed is NR1H4; the disease is obesity disorder.